NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Conference Coverage (AACR)



Antisense Therapy Targets Cancer Angiogenesis



May 26th, 1997

Antisense oligodeoxynucleotides (ODNs) targeting the angiogenic molecule, angiogenin (Ang), inhibit the establishment and metastatic spread of tumors in vivo.

Angiogenesis is critical to the growth of solid tumors and the development of metastasis. Interference with the process of tumor-induced angiogenesis has the potential to be an effective therapy for both primary and metastatic cancers. Currently, about nine angiogenic agents are being evaluated in clinical trials for the treatment of several angiogenesis-dependent diseases.

To develop additional angiogenesis inhibitors for cancer therapy, James W. Fett and colleagues from the Harvard Medical...


Source: Cancer Weekly (1997-05-26)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login